In the European pharmaceutical industry, there were 83 M&A deals announced in Q3 2023, worth a total value of $10.7bn, according to GlobalData’s Deals Database. The $5.7bn acquisition of Abcam by Danaher was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for Q3 2023 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.
In value terms, M&A activity in Europe increased by 5% in Q3 2023 compared with the previous quarter’s total of $10.2bn and rose by 102% as compared to Q3 2022. Related deal volume decreased by 24% in Q3 2023 versus the previous quarter and was 12% lower than in Q3 2022.
The top-ranked legal advisors supporting these M&A deals in Europe Q3 2023 were CMS Legal Services EEIG; Baker & McKenzie; Cuatrecasas, Goncalves Pereira with 10, 7, 6 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q3 2023 – Thematic Intelligence, buy the report here.